Pursuant to Regulation 30 and 33 of the SEBI (listing Obligation Disclosure Requirement) Regulations, 2015, (''Listing Regulations''), we wish to inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 1.2 pts more than its Civil Construction peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanta Industries reported its Q2 FY26 standalone results, with revenue from operations of Rs. 926.85 lakhs versus Rs. 185.98 lakhs in Q2 FY25 — a sharp jump. However, the company slipped into a standalone loss of Rs. 36.61 lakhs in Q2 FY26 (vs profit of Rs. 3.44 lakhs a year ago), making H1 FY26 standalone PAT marginally negative at Rs. -3.72 lakhs. Consolidated results, which include JV CKIM Pharma LLP, show Q2 FY26 revenue of Rs. 6,881.70 lakhs but a loss of Rs. 37.73 lakhs at the PAT level. The auditor issued a clean (unqualified) limited review report with no observations. Operating cash flow was positive on both standalone (Rs. 106 lakhs) and consolidated (Rs. 291 lakhs) basis. Total borrowings stand at roughly Rs. 3,604 lakhs standalone and Rs. 5,679 lakhs consolidated, putting debt-equity well above 2x.
Negative for shareholders in the short term — the company has swung to a loss at both standalone and consolidated levels in Q2 despite strong top-line growth, suggesting margin pressure and high finance costs (Rs. 14.58 lakhs consolidated). High leverage (D/E above 2x standalone and ~3.3x consolidated) remains a concern, though positive operating cash flow provides some comfort.